Chief Development Officer · Mirum Pharmaceuticals, Inc. (MIRM)

Lara Longpre

A named executive officer of Mirum Pharmaceuticals in every fiscal year CompBrief holds from FY2018 to FY2022. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2022

$1,507,496

Salary $450,000Stock awards $158,700

FY2019: $2,526,658

3rd of 4 named executive officers at Mirum Pharmaceuticals by FY2022 total.

4 named officers on file for Mirum Pharmaceuticals, FY2022

Lara Longpre’s pay file — $29

  • 3 fiscal years of pay, line by line
  • MIRM’s disclosed peer group of 21 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Mirum Pharmaceuticals’s whole pay program stands against its peers

  • Mirum Pharmaceuticals’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on MIRM→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed May 1, 2023 (DEF 14A).

Free

Get Lara Longpre’s full pay file as a PDF — free

More than this page: up to 10 years of Lara’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Lara Longpre compensation by year

Mirum Pharmaceuticals Summary Compensation Table · all 3 fiscal years held
In US dollars, as Mirum Pharmaceuticals reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2018FY2019FY2022
Salary$27,500$354,826$450,000
Bonus$0$155,300$0
Stock awards$0$0$158,700
Option awards$0$2,171,832$670,596
Non-equity incentive$0$0$216,000
Pension and deferred compensation$0$0$0
All other$0$0$12,200
Total$27,500$2,526,658$1,507,496

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Mirum Pharmaceuticals, Inc. DEF 14A filed May 1, 2023, accession 0001140361-23-022054, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Mirum Pharmaceuticals, Inc. filed document, accession 0001140361-23-022054. Every figure is read from that document and cited to the page and table it appears in. Filed May 1, 2023.

$28K
$2.5M
$1.5M
FY18
FY19
FY22
SalaryBonusNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2022 year-end
TypeUnvested unitsValue at year-endExercise price
RSU10,000$195,000—
RSU4,063$79,229—
Option60,000—$15.87
Option9,115—$6.27
Option14,084—$19.24
Option33,855—$19.19

Per the Outstanding Equity Awards at Fiscal Year-End table in Mirum Pharmaceuticals, Inc.'s FY2022 proxy; value at the fiscal year-end close, as the company printed it.

Mirum Pharmaceuticals’s named executive officers, FY2022

as the company reported each
Named executive officerRoleFY2022 total
Christopher PeetzPresident and Chief Executive Officer$4,402,664
Peter RadovichChief Operating Officer$1,561,446
Lara Longpre · this pageChief Development Officer$1,507,496
Pamela VigHead of Research and Development$1,507,496

The full Mirum Pharmaceuticals compensation record

free company brief

This page is one person within Mirum Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Mirum Pharmaceuticals proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Mirum Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Lara Longpre's compensation dossier · One-time report. No refunds.